# Biofund

> Biofund is a VC fund in Siena backing Genetics, Medical and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Siena, Italy
- Total investments: 5
- Last investment: May 2020
- Lead investor: 0%
- Last updated: Aug 2026

Biofund is a VC fund in Siena focused on Genetics and Medical. BIOFUND SpA, established by Fondazione Monte dei Paschi, Bank Monte dei Paschi , Finanziaria Senese di Sviluppo e Fidi Toscana, provides the initial seed capital for companies located in the incubator of Toscana Life Sciences in Siena.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Genetics | 3 | 60% |
| Medical | 2 | 40% |
| Health Care | 2 | 40% |
| Life Science | 2 | 40% |
| Biotechnology | 2 | 40% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 3 | 60% |
| Seed | 1 | 20% |
| Pre-Seed | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Canada | 2 | 40% |
| Italy | 1 | 20% |
| Denmark | 1 | 20% |
| Russian Federation | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EXE Engineering | EXE-Engineering for Environment. Miglioriamo i sistemi produttivi per rendere meno impattanti le attività umane |  | Pre-Seed | May 01, 2020 |  |
| RTM Diagnostika | Diagnostic microwave radio RTM-01-RESThe temperature and rate of growth of malignant tumorsCancer is the terrible disease of breast. That is why the full range of diagnostic measures in mammalogy aimed primarily at identifying it. It is known that the malignant tumor has a higher temperature compared with surrounding tissues. These data werefirst obtained Guture M. French scientist, who, after more than 550 invasive measurements demonstrated that malignancy is determined by its temperature is doubling time. Therefore, the most dangerous, rapidly growing tumors have a very high temperature. It is also known that thermal changes, usually preceded by structural changes. In particular, the thermal changes of the mammary glands come not a moment when the cancer reaches the required size, but much earlier. Studies have shown that even at the stage preceding the malignant growth, namely, when the cells have the expressed proliferation, accompanied by atypical changes, increases the density of microcapillary network, and as a consequence there is a local increase in temperature. Indisputable is the fact that patients with these changes have a high risk of malignancy. Many authors classify this condition as precancerous.The internal temperature - measure of angiogenesisIn 2003, Japanese scientists have shown that the temperature in the cancerous region determined by the density microcapillary network (microvessel density (MVD) [8]. This is the main parameter that characterizes angiogenesis. The density of the microcapillary network when proliferation atypia several times greater than the rate for normal tissues and characterizes the risk of malignancy. in addition, the microcapillary network density refers to the probability of transformation from noninvasive to invasive cancer, the probability of metastasis and tumor growth rate. Therefore, the internal temperature, as a measure of angiogenesis, provides important information about the development of cancer. | $166K | Seed | Jun 22, 2016 |  |
| Genizon BioSciences | Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. | $12M |  | Mar 29, 2006 |  |
| Exiqon | Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and thedevelopment of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences. | $20M |  | Jun 03, 2005 |  |
| Galileo Genomics | Galileo genomics is a Montreal-based private genetics company that conducts research in Quebecers of French descent using cutting-edge technologies, to identify genes that cause disease, thus providing validated targets for creation of innovative and more effective therapies and diagnostics. The Quebec founder population is the largest suchpopulation worldwide, which facilitates rapid patient recruiting. Because of the relatively late founding of the population in the 17th century, the relatively small number of founders, rapid early population growth, minimal intermarriage with other groups, and loss of some family lines while others expanded dramatically, the population is among the most homogeneous and has among the highest genetic sharing of all major founder populations. | $9M |  | Jan 08, 2004 |  |

5 of 5 investments shown.

## Co-investors
- [HBM Healthcare Investments](https://shizune.co/investors/profile/hbm-healthcare-investments-ag) — VC Fund, 2 deals together
- [Carnegie](https://shizune.co/investors/profile/carnegie) — VC Fund, 1 deal together
- [Carnegie Asset Management](https://shizune.co/investors/profile/carnegie-asset-management) — VC Fund, 1 deal together
- [Danske Bank](https://shizune.co/investors/profile/danske-bank) — VC Fund, 1 deal together
- [Illumina](https://shizune.co/investors/profile/illumina) — VC Fund, 1 deal together
- [LD Pensions](https://shizune.co/investors/profile/ld-pensions) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [Life Science Investors in Canada](https://shizune.co/investors/life-science-investors-canada)
- [Health Care VC Funds in Russian Federation](https://shizune.co/investors/health-care-vc-funds-russian-federation)
- [Medical VC Funds in Denmark](https://shizune.co/investors/medical-vc-funds-denmark)
- [Health Care VC Funds in Denmark](https://shizune.co/investors/health-care-vc-funds-denmark)
- [Life Science Investors in Denmark](https://shizune.co/investors/life-science-investors-denmark)
- [Life Science VC Funds in Denmark](https://shizune.co/investors/life-science-vc-funds-denmark)

## FAQ

### What does Biofund invest in?

Biofund invests primarily in Genetics, Medical and Health Care startups, most often at Funding Round and Seed stage. Most of the 5 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Biofund last invest?

The most recent investment recorded for Biofund closed in May 2020. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co